Granules India Ltd. Share Price

GRANULES INDIA: PHARMA MANUFACTURING AND MARGIN RECOVERY

is worth tracking as investors assess its quarterly performance and the outlook for pharmaceutical manufacturing. The company's business spans active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosage products. Growth depends on product demand, manufacturing utilisation, regulatory compliance and cost efficiency. What to monitor: - Revenue growth across business segments - Finished dosage contribution - US market demand and product approvals - Manufacturing costs and operating margins - Regulatory developments and capacity utilisation My view: The opportunity lies in improving product mix and manufacturing efficiency. However, regulatory compliance and earnings consistency remain essential factors when evaluating a pharmaceutical manufacturer. Disclaimer: This post represents my independent analysis based on publicly available information and is intended for educational and informational purposes only. I do not hold any position or financial interest in the security discussed as of the date of publication. Investors should independently verify the latest company disclosures and consider their investment objectives and risk profile before making any investment decision.

See More

Granules India Q2 profit jumps 39.2%, support holds

Granules India Q2 profit rose 39.2% to Rs 181.8 crore, while revenue grew 20.3%. Stock slipped 4.34%, with support at Rs 782 and resistance at Rs 860. Granules India Limited [

] reported a strong set of consolidated Q2 numbers for the September quarter, with net profit rising 39.2% year on year to Rs 181.8 crore from Rs 130.6 crore. Revenue also increased 20.3% to Rs 1,560 crore compared with Rs 1,297 crore in the corresponding quarter last year. Despite the strong earnings performance, the stock slipped up to 4.34% during trading on 3 November 2026, indicating volatility following the results. From a technical perspective, Granules India has been moving in a sideways consolidation phase over the past three months. Today's decline brought the stock closer to its important support zone of Rs 782, which remained intact despite the selling pressure. The daily chart shows that the stock recorded a low of Rs 785.10 before recovering to Rs 810.90. The immediate resistance is placed at Rs 860. Sustaining above Rs 782 will be important for maintaining the current consolidation structure, while a decisive breakout above Rs 860 could indicate a fresh upward move. A breakdown below support may weaken the technical setup. Disclaimer: Investments in securities are subject to market risk. This is for informational purposes only. Investors must verify information before investing and consider their financial position & risk profile.

See More

Granules India Shares Focus on Q2 Net Profit Jump

India Limited shares remained in sharp focus following the announcement of its financial performance for the second quarter ended September 30, 2026. The pharmaceutical manufacturer reported a robust 39.2% year-on-year increase in net profit after tax, reaching Rs 181.8 crore compared to Rs 131 crore in the corresponding period of the previous fiscal year. The bottom-line growth was supported by solid operational execution and strong demand across key regulated international markets. Consolidated revenue from operations expanded by 20.3% year-on-year to Rs 1,560 crore, up from Rs 1,297 crore recorded in Q2 FY26. Operating performance also witnessed significant gains, with earnings before interest, tax, depreciation, and amortization (EBITDA) increasing 21.3% to Rs 337.4 crore compared to Rs 278.1 crore in the prior year. The top-line acceleration was propelled by strong contributions from finished dosage formulations and active pharmaceutical ingredients, even as the company navigated localized input inflation and freight cost headwinds linked to West Asian logistics pressures. Alongside the earnings release, market participants closely evaluated regulatory developments as the United States Food and Drug Administration (USFDA) concluded a current Good Manufacturing Practice inspection at the company's finished dosage manufacturing facility in Gagillapur, Hyderabad. The inspection ended with the issuance of a Form FDA 483 containing eleven observations. While management prepares responses to address these regulatory remarks, the company's solid order book, ongoing product diversification, and strong demand pipeline continue to drive investor attention across pharmaceutical sector counters.

See More

Granules India Q2FY27 Results: PAT Jumps 39% YoY

reported a strong financial performance for Q2FY27, with consolidated net profit rising 39% year-on-year to ₹1,818 million. Revenue increased 20% to ₹15,600 million, reflecting continued business growth and operational momentum. However, standalone net profit declined 10% YoY, indicating a divergence between consolidated and standalone profitability. The results highlight the company's growth trajectory while bringing attention to its standalone earnings performance. Investors will closely monitor revenue growth, operating margins, cost management and business performance across key segments in the coming quarters to assess whether Granules India can sustain its consolidated earnings momentum.

See More

GRANULES INDIA IN FOCUS AFTER USFDA ISSUES 11 OBSERVATIONS

Shares of Granules India Ltd. will remain in focus on November 2 after the company disclosed that the US Food and Drug Administration issued 11 observations following an inspection of its finished dosage manufacturing facility at Gagillapur, Hyderabad. The USFDA conducted a Current Good Manufacturing Practice inspection at the facility between October 19 and October 30, 2026. The inspection concluded with the issuance of a Form FDA 483 containing 11 observations. This was the first USFDA inspection of the facility since the Warning Letter issued on February 26, 2025, following an earlier inspection conducted in August-September 2024. According to the company, none of the observations were related to data integrity or cross-contamination. Instead, they primarily concerned improvements in investigations, change control, process and equipment qualification, visual inspection controls and documentation practices. Granules India clarified that the observations have no impact on the manufacturing or distribution of products from the facility. The company will submit a comprehensive response to the USFDA within the stipulated 15 business days. Commenting on the inspection, the company said the process progressed constructively and that the observations could be addressed through appropriate responses and corrective and preventive actions (CAPA). It reiterated that quality remains a key priority and that it will continue to engage transparently with the regulatory agency. Meanwhile, the company's board of directors is scheduled to meet on Monday, November 2, 2026, to consider and approve the unaudited financial results for the second quarter and half-year ended September 30, 2026.

See More

Granules India Limited receives 11 USFDA observations

Granules India Limited received 11 observations following a USFDA inspection of its Gagillapur facility in Hyderabad. The company confirmed no data integrity or cross-contamination findings, with manufacturing and distribution unaffected. The inspection was conducted from October 19 to October 30, 2026, marking the first inspection since the warning letter issued on February 26, 2025. The observations relate to investigations, change control, equipment qualification, visual inspection and documentation. My view: The absence of data integrity concerns and operational disruption is encouraging. However, given the facility's previous warning letter, the company's corrective actions and the USFDA's response will be key to assessing regulatory risk. Granules India plans to submit its response within 15 business days. Separately, the company incorporated a wholly owned pharmaceutical subsidiary in Brazil to expand its presence in the market. Stance: Monitor regulatory updates before drawing firm conclusions on the facility's compliance outlook.

Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.

See More